Lovely Meds, Inc. dba Lovely Meds Warning Letter Details

Summary

Lovely Meds, Inc. was cited for unlawfully selling unapproved and misbranded compounded drugs—specifically semaglutide and tirzepatide products—over the internet to U.S. consumers. The company made false or misleading claims that its compounded products contained "the same active ingredient" as FDA-approved drugs (Wegovy, Ozempic, Zepbound, and Mounjaro), violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act by implying equivalence to approved products when compounded drugs are not FDA-approved. These misbranded products were introduced into interstate commerce in violation of section 301(a) of the FDCA.